Aeolus Pharmaceuticals Inc.' AEOL 10150 Highlighted in Nature Genetics Publication
Published: Apr 18, 2007
LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today that a new report published in the medical journal, Nature Genetics (Tong et al. Nature Genetics 39:476-485, 2007), showed that Aeolus Pharmaceuticals’ lead compound AEOL 10150 (MnTDEIP) can improve survival in fruit flies genetically lacking the neurofibromatosis-1 (NF1) gene. These mutant flies had reduced mitochondrial function and increased production of reactive oxygen species that was associated with a greatly shortened lifespan. Dr. Douglas Wallace’s team at the University of California-Irvine concluded that the increased mitochondrial Reactive Oxygen Species (ROS) production resulting from NF1 mutations could be an important factor in the generation of neurofibromas. If so, then the suppression of mitochondrial ROS production through the treatment with catalytic antioxidants such as AEOL 10150 may provide a powerful new approach to treat NF1, as well as other cancers.